Feb 3, 2026 07:00AM
Feb 3, 2026 07:00AM
Feb 3, 2026 04:11AM
Feb 3, 2026 02:30AM
Dec 2, 2025 09:18AM
Dec 2, 2025 09:18AM
Oct 1, 2025 07:00AM FDA accepts ENHERTU application for early-stage breast cancer treatment
Oct 1, 2025 07:00AM
Sep 24, 2025 07:00AM
Sep 24, 2025 02:30AM
Jul 28, 2025 07:01AM
Jul 28, 2025 07:00AM
Jan 13, 2025 07:00AM
Jan 13, 2025 06:09AM AstraZeneca (AZN) Reports Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Jan 13, 2025 02:00AM
Dec 11, 2024 09:44AM
Dec 6, 2024 07:00AM
Dec 6, 2024 06:14AM
Oct 3, 2024 07:04AM
Oct 3, 2024 07:00AM
Oct 3, 2024 06:11AM AstraZeneca (AZN) reports Calquence granted Priority Review in the US for patients with untreated mantle cell lymphoma
Oct 1, 2024 07:06AM
Oct 1, 2024 07:00AM
Oct 1, 2024 06:19AM
Oct 1, 2024 02:00AM
Sep 13, 2024 04:00AM
Aug 15, 2024 07:02AM
Aug 15, 2024 07:00AM IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US
Jun 10, 2024 07:00AM
Jun 10, 2024 06:03AM
Jun 10, 2024 04:36AM
Apr 2, 2024 07:00AM
Apr 2, 2024 05:36AM
Apr 2, 2024 02:00AM
Feb 19, 2024 07:10AM Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer
Feb 19, 2024 02:00AM
Jan 29, 2024 07:00AM
Jan 29, 2024 06:00AM
Jan 29, 2024 02:00AM
Oct 24, 2023 07:00AM
Oct 24, 2023 05:46AM
Oct 16, 2023 07:00AM TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer
Oct 16, 2023 06:16AM
Jul 28, 2023 07:05AM
Jun 12, 2023 07:00AM
Jun 12, 2023 05:32AM
Jun 8, 2023 05:35PM
Jun 8, 2023 05:31PM
Dec 21, 2022 06:05AM AstraZeneca (AZN) Announces Lynparza with Abiraterone Approved in EU for mCRPC
Dec 15, 2022 05:53AM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All